Drug Profile
Bupivacaine sustained-release - MedinCell
Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator MedinCell S.A.
- Class Analgesics; Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Postoperative pain
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Postoperative pain in France (Parenteral), prior to September 2023 (MedinCell S.A. pipeline, September 2023)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Postoperative-pain in France (Parenteral, Injection)
- 12 Aug 2016 Chemical structure information added